Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

By H. Shigematsu, Takao Takahashi, M. Nomura, K. Majmudar, Makoto Suzuki, Hue Lee, I. Wistuba, K. Fong, S. Toyooka, N. Shimizu and 3 more. Cancer Research, 2005

694 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/cfb1b3a93b5315b0c87f34cb11f4ecef4876bf16

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Adi F. Gazdar
2. G. Shapiro
3. M. Moasser
4. H. Shigematsu
5. Lewis C. Cantley
6. N. Iqbal
7. N. Iqbal
8. T. Yuan

In Pulmonary and Respiratory Medicine

1. Adi F. Gazdar

Citations in the corpus

• Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications (2014, neutral): “The mutations targeted never or light smokers, oriental ethnicity, and female gender [51, 52].”
• Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment (2009, neutral): “Notably, several insertions in exon 20 that drive constitutive EGFR activation are detected in lung cancer patients (Shigematsu et al., 2005; Greulich et al., 2005).”
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models (2008, background): “BIBW2992 is one such inhibitor active against both EGFR and HER2.”
• The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis (2007, background): “Somatic mutations within the HER2 kinase domain have been described in a small subset of lung cancers, predominantly in Asian populations, and very rarely in gastric, colorectal and breast cancers (Figure 1, region D) (Stephens et al., 2004; Shigematsu et al., 2005; Lee et al., 2006).”
• Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers (2006, background): “Only 3 types of mutant cell lines (in-frame deletions and L858R missense mutation with or without T790M) are available to date.(20) However, there are relatively few cases with the rare mutations, we do not know the relation between these muta-”